← Back to Search

Radiation Therapy

Adaptive Radiation Therapy for Genitourinary Cancer (ARTGU Trial)

N/A

Waitlist Available

Led By Peter Chung, MD

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologic diagnosis of adenocarcinoma of the prostate after radical prostatectomy: Clinical stage pT3, pT4, or pT2 with positive margin; OR, any p-stage with persistently elevated post-operative PSA > 0.05ng/mL; OR, a delayed rise in PSA post-operative

Histologic diagnosis of transitional cell carcinoma of the bladder with intact bladder and: Clinical stage cT2, cT3, cT4, and N0 or N1

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

ARTGU Trial Summary

This trial will use Adaptive Radiation Therapy to account for any shifts in the target volume for prostate or bladder cancer patients who receive pelvic nodal radiotherapy.

Who is the study for?

This trial is for adults with certain stages of bladder or prostate cancer. For bladder cancer, it's those who haven't had their bladder removed and are at stage cT2 to cT4 without distant metastases. Prostate cancer patients must have had surgery already but still show signs of the disease or rising PSA levels. People can't join if they've had previous chemo, pelvic radiation, inflammatory bowel disease, or any evidence of the cancer spreading far.Check my eligibility

What is being tested?

The study tests Adaptive Radiation Therapy (ART) in treating pelvic genitourinary cancers by adjusting treatment plans based on MRI and CBCT scans taken during the first week of radiotherapy. The goal is to see how well ART works for these cancers and monitor its effects over five years using follow-up questionnaires and standard PSA testing.See study design

What are the potential side effects?

While not explicitly listed in your information provided, side effects from radiation therapy generally include fatigue, skin reactions in treated areas, inflammation of organs like the bladder or rectum (radiation cystitis or proctitis), as well as potential long-term changes to bowel and urinary function.

ARTGU Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My prostate cancer was confirmed after surgery and shows signs of aggressive behavior or rising PSA levels.

Select...

My bladder cancer is at a specific stage and has not spread far.

ARTGU Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dosimetry

Secondary outcome measures

Biochemical Control in Prostate Patients

Bladder Cancer Patients' Quality of Life Function

Feasibility of the use of Fiducial markers for bladder RT: quality of target delineation using fiducial markers

+3 more

ARTGU Trial Design

1Treatment groups

Experimental Treatment

Group I: Adaptive Radiation TherapyExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Adaptive Radiation Therapy

2016

N/A

~80

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,468 Previous Clinical Trials

484,490 Total Patients Enrolled

63 Trials studying Prostate Cancer

15,400 Patients Enrolled for Prostate Cancer

Peter Chung, MDPrincipal InvestigatorPrincess Margaret Cancer Centre - University Health Network

3 Previous Clinical Trials

326 Total Patients Enrolled

1 Trials studying Prostate Cancer

17 Patients Enrolled for Prostate Cancer

Media Library

Prostate Cancer Research Study Groups: Adaptive Radiation Therapy

Prostate Cancer Clinical Trial 2023: Adaptive Radiation Therapy Highlights & Side Effects. Trial Name: NCT03909893 — N/A

Adaptive Radiation Therapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03909893 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is registration for this research endeavor still open?

"Clinicaltrials.gov states that this trial is currently not recruiting patients, as the last time it was updated on April 7th 2022 predates its initial post date of October 1st 2023. However, there are a multitude of other medical trials in search for participants at present numbering 1038 cases."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer

2023. "A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03909893.